vs
NEUROCRINE BIOSCIENCES INC（NBIX）与Rivian Automotive, Inc.（RIVN）财务数据对比。点击上方公司名可切换其他公司
Rivian Automotive, Inc.的季度营收约是NEUROCRINE BIOSCIENCES INC的1.6倍（$1.3B vs $805.5M），NEUROCRINE BIOSCIENCES INC净利率更高（19.1% vs -63.1%，领先82.1%），NEUROCRINE BIOSCIENCES INC同比增速更快（28.3% vs -25.8%），NEUROCRINE BIOSCIENCES INC自由现金流更多（$386.0M vs $-1.1B），过去两年NEUROCRINE BIOSCIENCES INC的营收复合增速更高（25.0% vs 3.3%）
Neurocrine Biosciences是1992年成立的美国生物制药企业，总部位于加利福尼亚州圣地亚哥，截至2024年10月首席执行官为Kyle Gano。公司专注于神经及内分泌相关疾病的疗法研发，旗下药物缬苯那嗪（商品名Ingrezza）于2017年获美国批准，用于治疗成人迟发性运动障碍。
Rivian Automotive是2009年成立的美国电动汽车制造商及汽车科技企业，主打基于自研滑板平台打造的电动SUV、皮卡及EDV电动配送货车，旗下R1T皮卡于2021年末正式开启交付，还计划于2023年底前在美国和加拿大布局专属充电网络，其平台可适配新车型也可对外授权使用。
NBIX vs RIVN — 直观对比
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $805.5M | $1.3B |
| 净利润 | $153.7M | $-811.0M |
| 毛利率 | 97.8% | 9.3% |
| 营业利润率 | 26.2% | -64.8% |
| 净利率 | 19.1% | -63.1% |
| 营收同比 | 28.3% | -25.8% |
| 净利润同比 | 49.1% | -9.0% |
| 每股收益（稀释后） | $1.49 | $-0.66 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $805.5M | $1.3B | ||
| Q3 25 | $794.9M | $1.6B | ||
| Q2 25 | $687.5M | $1.3B | ||
| Q1 25 | $572.6M | $1.2B | ||
| Q4 24 | $627.7M | $1.7B | ||
| Q3 24 | $622.1M | $874.0M | ||
| Q2 24 | $590.2M | $1.2B | ||
| Q1 24 | $515.3M | $1.2B |
| Q4 25 | $153.7M | $-811.0M | ||
| Q3 25 | $209.5M | $-1.2B | ||
| Q2 25 | $107.5M | $-1.1B | ||
| Q1 25 | $7.9M | $-545.0M | ||
| Q4 24 | $103.1M | $-744.0M | ||
| Q3 24 | $129.8M | $-1.1B | ||
| Q2 24 | $65.0M | $-1.5B | ||
| Q1 24 | $43.4M | $-1.4B |
| Q4 25 | 97.8% | 9.3% | ||
| Q3 25 | 98.2% | 1.5% | ||
| Q2 25 | 98.4% | -15.8% | ||
| Q1 25 | 98.4% | 16.6% | ||
| Q4 24 | 98.5% | 9.8% | ||
| Q3 24 | 98.7% | -44.9% | ||
| Q2 24 | 98.4% | -38.9% | ||
| Q1 24 | 98.5% | -43.8% |
| Q4 25 | 26.2% | -64.8% | ||
| Q3 25 | 30.1% | -63.1% | ||
| Q2 25 | 21.2% | -85.5% | ||
| Q1 25 | 4.1% | -52.8% | ||
| Q4 24 | 22.6% | -38.1% | ||
| Q3 24 | 29.5% | -133.8% | ||
| Q2 24 | 24.6% | -118.7% | ||
| Q1 24 | 19.3% | -123.3% |
| Q4 25 | 19.1% | -63.1% | ||
| Q3 25 | 26.4% | -75.3% | ||
| Q2 25 | 15.6% | -85.7% | ||
| Q1 25 | 1.4% | -44.0% | ||
| Q4 24 | 16.4% | -42.9% | ||
| Q3 24 | 20.9% | -125.9% | ||
| Q2 24 | 11.0% | -125.8% | ||
| Q1 24 | 8.4% | -120.1% |
| Q4 25 | $1.49 | $-0.66 | ||
| Q3 25 | $2.04 | $-0.96 | ||
| Q2 25 | $1.06 | $-0.97 | ||
| Q1 25 | $0.08 | $-0.48 | ||
| Q4 24 | $1.00 | $-0.67 | ||
| Q3 24 | $1.24 | $-1.08 | ||
| Q2 24 | $0.63 | $-1.46 | ||
| Q1 24 | $0.42 | $-1.48 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $713.0M | $6.1B |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $3.3B | $4.6B |
| 总资产 | $4.6B | $14.9B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
| Q4 25 | $713.0M | $6.1B | ||
| Q3 25 | $340.2M | $7.1B | ||
| Q2 25 | $264.0M | $7.5B | ||
| Q1 25 | $194.1M | $7.2B | ||
| Q4 24 | $233.0M | $7.7B | ||
| Q3 24 | $349.1M | $6.7B | ||
| Q2 24 | $139.7M | $7.9B | ||
| Q1 24 | $396.3M | $7.9B |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | $5.5B | ||
| Q1 24 | — | $4.4B |
| Q4 25 | $3.3B | $4.6B | ||
| Q3 25 | $3.0B | $5.1B | ||
| Q2 25 | $2.7B | $6.1B | ||
| Q1 25 | $2.5B | $6.2B | ||
| Q4 24 | $2.6B | $6.6B | ||
| Q3 24 | $2.7B | $5.9B | ||
| Q2 24 | $2.5B | $6.8B | ||
| Q1 24 | $2.4B | $8.1B |
| Q4 25 | $4.6B | $14.9B | ||
| Q3 25 | $4.3B | $15.2B | ||
| Q2 25 | $3.9B | $15.6B | ||
| Q1 25 | $3.7B | $15.5B | ||
| Q4 24 | $3.7B | $15.4B | ||
| Q3 24 | $3.5B | $14.3B | ||
| Q2 24 | $3.3B | $15.4B | ||
| Q1 24 | $3.5B | $15.7B |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 0.81× | ||
| Q1 24 | — | 0.55× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $388.4M | $-681.0M |
| 自由现金流经营现金流 - 资本支出 | $386.0M | $-1.1B |
| 自由现金流率自由现金流/营收 | 47.9% | -89.0% |
| 资本支出强度资本支出/营收 | 0.3% | 36.0% |
| 现金转化率经营现金流/净利润 | 2.53× | — |
| 过去12个月自由现金流最近4个季度 | $743.9M | $-2.5B |
8季度趋势，按日历期对齐
| Q4 25 | $388.4M | $-681.0M | ||
| Q3 25 | $227.5M | $26.0M | ||
| Q2 25 | $102.0M | $64.0M | ||
| Q1 25 | $64.8M | $-188.0M | ||
| Q4 24 | $242.5M | $1.2B | ||
| Q3 24 | $158.0M | $-876.0M | ||
| Q2 24 | $64.6M | $-754.0M | ||
| Q1 24 | $130.3M | $-1.3B |
| Q4 25 | $386.0M | $-1.1B | ||
| Q3 25 | $214.3M | $-421.0M | ||
| Q2 25 | $89.5M | $-398.0M | ||
| Q1 25 | $54.1M | $-526.0M | ||
| Q4 24 | $235.2M | $856.0M | ||
| Q3 24 | $149.9M | $-1.2B | ||
| Q2 24 | $53.0M | $-1.0B | ||
| Q1 24 | $119.1M | $-1.5B |
| Q4 25 | 47.9% | -89.0% | ||
| Q3 25 | 27.0% | -27.0% | ||
| Q2 25 | 13.0% | -30.5% | ||
| Q1 25 | 9.4% | -42.4% | ||
| Q4 24 | 37.5% | 49.4% | ||
| Q3 24 | 24.1% | -131.9% | ||
| Q2 24 | 9.0% | -89.6% | ||
| Q1 24 | 23.1% | -126.5% |
| Q4 25 | 0.3% | 36.0% | ||
| Q3 25 | 1.7% | 28.7% | ||
| Q2 25 | 1.8% | 35.5% | ||
| Q1 25 | 1.9% | 27.3% | ||
| Q4 24 | 1.2% | 18.9% | ||
| Q3 24 | 1.3% | 31.7% | ||
| Q2 24 | 2.0% | 24.4% | ||
| Q1 24 | 2.2% | 21.1% |
| Q4 25 | 2.53× | — | ||
| Q3 25 | 1.09× | — | ||
| Q2 25 | 0.95× | — | ||
| Q1 25 | 8.20× | — | ||
| Q4 24 | 2.35× | — | ||
| Q3 24 | 1.22× | — | ||
| Q2 24 | 0.99× | — | ||
| Q1 24 | 3.00× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
NBIX
| INGREZZA Net Product Sales | $653.8M | 81% |
| CRENESSITY Net Product Sales | $135.4M | 17% |
| Other Income | $12.6M | 2% |
| Collaboration Revenue | $7.2M | 1% |
RIVN
| Automotive Segment | $839.0M | 65% |
| Software And Services Segment | $447.0M | 35% |
| Regulatory Credits | $30.0M | 2% |
